Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Reverse split will work ! It will get inst and funds to buy the stock. How many funds are going to buy a OTC stock ??
Reverse split does not work for companies that do it to stay from getting too low or delisted.
It does work if company is doing it because they expect to grow strongly, and want funds to buy in.
Time for them to announce a reverse split 6:1..get it over $5 on Nasdaq. Get institutions and funds to start buying. Market cap should be about $200M with where the company is now, if it weren't on OTB.
This is not a biotech that needs expensive multi year trials, and then long FDA approvals. In biotechs, animal models work but drug often fails in phase 2 or 3.
AC5 has been tested on animals, and humans for safety already. Animals bleed just like humans last time I checked...and medical devices get approved much more quickly. They don't need 100s of patients to test this either.
Getting past results and CE and PMA is given for 2016. The question is how do they market this. They need to get the right partners. The product will sell itself for multiple applications.
With so many warrants sold earlier this month, they should have good cash to take this to market this year.
I don't think results will come end of Aug...likely beginning. I see buyout in about $250M in 2016. Still very low buyout price for potential of > $1 billion over next 2-3 years.
volume is tapering off...seems it might trend in the low to mid 0.60s for rest of July, and then ramp up in August. Results expected early August IMO
I don't agree about selling pressure once results are released....seen lots of stock go higher after offerings made after positive results. Market starts to factor in potential. ARTH has initial potential of $500M with positive results and CE and PMA FDA approval...longer term over $1 billion.
What is market cap for ARTH...Their website says $69M, but Yahoo Finance says $79M. I assume website is correct ?
Glad it sold off from .90 back to .60....the run up from .40 to .90 was not warranted, no news, huge run up in short period. Selloff since then is VERY HEALTHY. This forms base to run up again, as news coming likely before end of month
Volatility to be expected since they just had a 25% cut last week..Stock at 75M market cap with potential to be in multi billions very quickly. Results will come before end of month, CE approval within 30 days after that. They are also working towards PMA with FDA. For medical devices, should be all quick. MM playing with the stock, keep eye on the prize. My estimate is stock is 2-3x current price later in 2016 once CE and PMA is done.
ok right..so you are saying Matrix has made false statements...but there is no way a MIT graduate will make false comments ? Maybe Matrix has the SAME product, and ARCH is just trying to catch up but pumping as the only one with this unique product.
It doesn't matter Rejis99 what you 'assume'....3DMatrix description of their product is EXACTLY the same as ARCH. And you claim they did not do any human trials...how in the heck are they selling to Europe, US, UK etc ? They are even getting distributors. They got CE without human trials ? I doubt it.
The only way to find out if this product is different is by calling ARCH IR.
I am not short. I was going to be long, but there are TOO many questions and issues with this company. Another company in the same zip code, already has this same EXACT product ??? and its already CE approved ??? What exactly is ARCH trying to prove here.
Sorry company is called 3d matrix.
http://www.puramatrix.com/
The ability to stop and control bleeding is critically important to all surgical procedures and to the practice of medicine in general. Based on the self-assembling peptide platform technology of PuraMatrix®, 3-D Matrix has obtained CE mark approval for the surgical hemostatic agent PuraStat®. PuraStat® gels upon blood contact and stops bleeding (hemostasis) via mechanical blocking of the bleeding site for diffuse bleeds while allowing full, transparent view of the target area. PuraStat® has a number of unique features that distinguish it from existing products.
Guys, did you consider this.
MIT is giving away its license to other companies too. Matrix plus is a company based close to Boston, just like this one. They have the SAME technology, and they are CE approved already. Well, J&J didn't buy them out.
ARTH needs to get CE approval, get marketing done in Europe, get a partner to sponsor, start additional trials on surgery. This product is NOT going to be successful externally...read their website. Its all about internal control, without clotting. Plus they have only funds till October 2106.
I did my research...there is good amount of pumping here.
Matrix has been discussed on this board earlier too...search it up.
Anyone heard from IR lately ? Sent them an email late last week, but no response. Asking the same question...any ideas when Dr will report 12/24wk data.
Isn't this a bit of pumping ?? Their trial is based on dermatology, not surgery. Isn't their main advantage surgery ? No clotting, clear vision etc.
For burns, cuts, ulcers wouldn't you need a solution that DOES clot ? for healing ? Am I missing something here.
I also assume they would need to do another trail either in Europe or US for surgery.
Another point about licensing...ARTH does not hold the patent on the technology...MIT does. They are licensing it from MIT. ARTH is getting some patents on its application.
If and when AC5 gets acquired, won't the royalties go to MIT ? Not sure what ARCH will get out of it.
what is your analysis of AC5 vs. Clotfoam ?
Clotform used in surgeries.
http://www.biomedic.net/Research&Dev/clotfoam2.htm
16 seconds to homostatis.
They got IND from FDA. So its a drug, not medical device.
http://www.pr.com/press-release/514642
2014 they started trials, never completed I am guessing.
https://clinicaltrials.gov/ct2/show/NCT02264730
Biomedica plans to complete Phase I in the course of 2013 and initiate Phase 2 clinical trials as an adjunct to hemostasis in the first quarter of 2014. The company has requested Fast Track Designation for ClotFoam. This designation is reserved for drugs that advance novel technologies, and are expected to provide significant therapeutic advantages over existing products while addressing unmet medical needs
Check out Clotfoam...used in surgeries.
Time to hemostasis (s)
16.0 ± 6.0
So they can get it sealed in 16 seconds. Why does ARTH say all other treatments are over couple of minutes ?
Also, they applied for new drug (IND) with FDA. So FDA considers this as a drug and not a device like Europe. Means when if ARTH wants to apply in US, they need to go through the long process of new drug investigation, and not new 'device'.
Guys, am not long or short..but do your research. LOTS of competition out there, and not all have the kind of drawbacks as listed by ARCH company. Even if they do get approved by Europe and US, I doubt they will get the 25% of 4 billion market people are talking about. Taking market from J&J and big pharmas is not going to be easy, if there is subtle differences.
Anyone know how ARTH is different than quikclot ? Their website says it is used by military, hospitals.
No competition is not correct. There are lots of competition. They have a superior product, but there is lots of competition. Read my earlier post...my concerns with ARTH
They may have a superior product....better than all the competitors.
BUT...here is the issue
They only have funding to take it through EU trials, and CE approval. They have $ till Oct, so no $ to market it in Europe.
Not sure if they need another trial for US. But they won't be getting US approval by Oct. That will likely take more time.
I am assuming no US company is going to buy them until they get US Approval. That is the problem.
Another problem...even though they have better product, competitors likely will not buy them. They have their own products ! Why kill their own and buy this ? j&j etc are not going to buy them.
So too many issues -
[1] No funding beyond Oct
[2] No funding for Europe marketing. Need quite some $ for that
[3] No buyout till US approval
[4] Likely competition will not buy them. Only chance is a buyout from company not in this biz today. That reduces the list significantly
[5] Market cap already $45M with no revenue today Less
From my experience, high volume buying usually always means insiders or those who know inside news are buying, ahead of news coming up. Would expect BP, some great news by this week.
This is not retail buying....institutions or insiders are loading up, because they know something.
Same PHD Lane Simonian commenting on AVX 2-73 results back in Nov (and comments to thestreet article) -
I am not a huge fan of the placebo effect argument. A placebo can make someone feel better; it can to a certain degree actually make them better by reducing stress. But it is doubtful that a person's memory with Alzheimer's disease actually improves based on a placebo.
I believe in double-blinded randomized placebo controlled trials because it takes one more argument out of the arsenal of those who doubt the results. On the other hand, a placebo controlled trial can confound results. If several members of the placebo branch of a trial were on an antioxidant diet (which might even include the polyphenols in coffee), their results might not be that different than the drug/natural product group and make the results from the latter look not significant.
I don't know enough about chemistry to say how effective an antioxidant ANAVEX's drug is and it is possible the results won't hold up with more people and over a longer period of time. I do think they have the right mechanism of action and that a larger trial is warranted.
Old comments I found from PHD Lane Simonian, from 05/08/15.
In regards to the overall picture, I think the researchers at ANAVEX have it right.
http://www.anavex.com/?news=anavex-announces-report-expanding-opportunity-for-therapeutic-application-of-anavex-compounds
ANAVEX 2-73 has been shown to provide protection from oxidative stress, which damages and destroys neurons and is believed to be a primary cause of Alzheimer's disease. Research in recent years indicates that oxidative stress is a precursor to amyloid-beta plaques and tau (Neuro-Fibrillary Tangles or NFT) and, as such, is the appropriate therapeutic target. ANAVEX 2-73 is not focused on reducing or dissolving amyloid-beta protein, unlike drug candidates from other biopharmaceutical companies that have recently produced disappointing clinical results.
Anybody know difference between 2-73 AND 3-71 ? Why did they take 2-73 through phase 2 first ? 3-71 also seems to be great in preclinical for AZ.
Why bother with 2-73 PLUS patent ???
They already have 2-73 patent. SOC is already generic today. What is the point ?
the rejection was for 2-73 PLUS -
This invention concerns a dosage form comprising a therapeutically neuroprotective amount of A2-73 and a neuroprotective amount of at least one cooperating acetylcholinesterase inhibitor selected from the group consisting of donepezil, galantamine, rivastigmine, or memantine and method of use.
Does anyone have the application patent ID for 2-73 itself ?
anyone have the patent ID for 2-73 so we can search it up on the patent site ? Was 13/940,352 for 2-73 plus ? thanks.
Was there a separate patent for 2-73, and 2-73 plus ?